MediPharm Labs Corp. MEDIF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score

43/100

1/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

MediPharm Labs Corp. (MEDIF) , 前瞻盈利收益率 769.23%.

本页证实的标准:

VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
前瞻市盈率 0.1

SharesGrow 综合评分： 40/100 其中 1/7 项标准通过。

SharesGrow 7-Criteria Score

43/100

SG Score

View full scorecard →

—

价值

N/A

No coverage

—

未來

N/A

No coverage

✗

过去

0/100

→ Income

健康

67/100

Debt-to-Equity & liquidity

→ Health

✗

护城河

36/100

→ Income

✓

成长

100/100

→ Income

✗

收入

10/100

→ Income

估值概览 — MEDIF

估值倍数

P/E (TTM)0.0

前瞻 P/E0.1

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率0.47

EV/EBITDA0.0

每股数据

EPS (TTM)$-0.03

前瞻 EPS（预估）$0.37

每股账面价值$0.00

每股营收$0.10

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

Forward Earnings Yield769.23%

股息收益率0.00%

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2017	$0.00	$0.00	$0.00	-
2018	$-0.12	$10.2M	$-8.39M	-82.2%
2019	$0.01	$129.25M	$1.13M	0.9%
2020	$-0.48	$36.01M	$-67.11M	-186.4%
2021	$-0.22	$21.71M	$-54.8M	-252.4%
2022	$-0.11	$22.12M	$-29.98M	-135.6%
2023	$-0.04	$33.06M	$-13.08M	-39.6%
2024	$-0.03	$41.96M	$-10.69M	-25.5%